Study of Cagrilintide Effects on Appetite and Energy Intake in Adults with Overweight or Obesity

What this Trial Is About

Researchers are studying how cagrilintide, a medicine given by injection, affects food intake and appetite in adults with overweight or obesity. The goal is to understand changes in energy intake and appetite over a treatment period. This is a phase 1 clinical trial sponsored by Novo Nordisk AS, designed to gather early information about cagrilintides effects compared to a placebo. Participants will be randomly assigned to one of two groups one group will receive cagrilintide injections once a week for up to 17 weeks, and the other group will receive placebo injections that look like the medicine but contain no active drug. The treatment phase lasts about 17 weeks, and participants will be monitored throughout this time to assess the study medicines impact. During the study, participants will have meals where their energy intake is measured at breakfast, lunch, dinner, and snack times. Appetite will be evaluated using questionnaires and scales that assess hunger, fullness, and cravings. Researchers will track changes from baseline to the end of treatment. The total study duration is about 30 weeks, including screening and follow-up, with safety and health monitoring occurring throughout.

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity